Xinhua News Agency: China's monetary policy has changed from "prudent" to "moderately loose" to send a positive signal.Say a data, since 2010, A shares have opened higher by more than 2% for 13 times, including 11 times of high opening and low walking, and only 2 times of high opening and high walking! Just get used to it, this is the urine of big A. Actually, it was good yesterday, which was in line with the slow cow. It is estimated that some people are still breathing a sigh of relief. If it rises like the beginning of October, they will not be able to sleep! You know, yesterday was a slow cow.Ningde's business in Europe has made progress. Through cooperation with local European giants, it has invested 30 billion RMB, with each party holding 50% of the shares. This is a new mode of exploring the sea! It is worth noting that this cooperation with Stellantis is mainly to supply lithium iron batteries and drive a new round of electrification in Europe through Ferrous lithium phosphate parity technology, which is a new opportunity from 0 to 1.
Guoxin Technology: shareholders such as the National Fund intend to reduce their holdings by no more than 3%;Second, Contemporary Amperex Technology Co., Limited's enlargement trick: special dividends for factories in EuropeWentai Technology: Shareholders plan to reduce their holdings by no more than 2%;
Second, Contemporary Amperex Technology Co., Limited's enlargement trick: special dividends for factories in EuropeAmong them, the biggest benefit is the biomedical industry. It is necessary to set up a M&A fund with a scale of 10 billion, which is specifically aimed at the merger and reorganization of the biomedical industry! The focus is on local enterprises in Shanghai, especially the biomedicine of listed companies in Shanghai.Among them, the biggest benefit is the biomedical industry. It is necessary to set up a M&A fund with a scale of 10 billion, which is specifically aimed at the merger and reorganization of the biomedical industry! The focus is on local enterprises in Shanghai, especially the biomedicine of listed companies in Shanghai.
Strategy guide
12-13
Strategy guide
Strategy guide